{"id":7106,"date":"2020-01-12T19:36:07","date_gmt":"2020-01-12T18:36:07","guid":{"rendered":"https:\/\/www.endoscopy-campus.com\/?post_type=ec-news&p=7106"},"modified":"2020-01-12T19:38:19","modified_gmt":"2020-01-12T18:38:19","slug":"review-and-meta-analysis-finds-fit-crc-sensitivity-lower-in-stage-i-and-t1","status":"publish","type":"ec-news","link":"https:\/\/www.endoscopy-campus.com\/en\/ec-news\/review-and-meta-analysis-finds-fit-crc-sensitivity-lower-in-stage-i-and-t1\/","title":{"rendered":"Review and Meta-analysis Finds FIT CRC Sensitivity Lower in Stage I and T1"},"content":{"rendered":"\n

Douglas K. Rex, MD, FASGE reviewing Niedermaier T, et al. Am J Gastroenterol 2019 Dec 10.<\/strong><\/em><\/p>\n\n\n\n

Fecal immunochemical test (FIT) sensitivity for colorectal cancer (CRC) is often cited at about 80%, using the 20 microgram Hgb\/g feces cut-off. However, it is important to know the stage-specific performance because detection of early stages has greater value than detection of late stages.<\/p>\n\n\n\n

In a systematic review and meta-analysis of 44 studies, the pooled sensitivity estimates for stages I, II, III, and IV were 73%, 80%, 82%, and 79%, respectively, with significant differences between stages I versus II and I versus III. The pooled sensitivities by T stage showed more striking differences: the respective sensitivities for T1, T2, T3, and T4 were 40%, 79%, 83%, and 66%, with significantly lower sensitivity for T1 than each of the higher T stages.<\/p>\n\n\n\n

<\/p>\n\n\n\n

<\/div>\n\n\n\n

COMMENT
This analysis is informative, suggesting that FIT sensitivity for T1 cancers is comparable to FIT sensitivity for advanced adenomas. The study is likely to be viewed as a modest setback to the rising enthusiasm for FIT as a CRC screening test.<\/p><\/blockquote><\/figure>\n\n\n\n

<\/div>\n\n\n\n

Note to readers: At the time we reviewed this paper, its publisher noted that it was not in final form and that subsequent changes might be made. <\/p>\n\n\n\n

<\/div>\n\n\n\n
\"\"<\/figure>
\n

Douglas K. Rex, MD, FASGE <\/p>\n<\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n

CITATION(S) <\/h2>\n\n\n\n

Niedermaier T, Balavarca Y, Brenner H. Stage-specific sensitivity of fecal immunochemical tests for detection colorectal cancer: systematic review and meta-analysis.\u00a0Am J Gastroenterol<\/em>\u00a02019 Dec 10. (Epub ahead of print) (https:\/\/doi.org\/10.14309\/ajg.0000000000000465<\/a>) <\/p>\n","protected":false},"excerpt":{"rendered":"

Douglas K. Rex, MD, FASGE reviewing Niedermaier T, et al. Am J Gastroenterol 2019 Dec 10. Fecal immunochemical test (FIT) sensitivity for colorectal cancer (CRC) is often cited at about 80%, using the 20 microgram Hgb\/g feces cut-off. However, it is important to know the stage-specific performance because detection of early stages has greater value … Read more<\/a><\/p>\n","protected":false},"template":"","categories":[1768,1769],"tags":[1859,1858],"class_list":["post-7106","ec-news","type-ec-news","status-publish","hentry","category-asge-journal-scan","category-asge-kolon","tag-crc-screening-test","tag-fit-crc"],"_links":{"self":[{"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/ec-news\/7106","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/ec-news"}],"about":[{"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/types\/ec-news"}],"wp:attachment":[{"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/media?parent=7106"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/categories?post=7106"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/tags?post=7106"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}